


## Patent Claims

1. Compounds of the general formula U-V-W, wherein U refers to the formula (I),



wherein

A is a optionally substituted 5- or 6-membered heteroarylen ring;

X is an oxygen atom, a sulfur atom, a group of the formula NR<sup>13</sup> or CR<sup>14</sup>R<sup>15</sup>;

Y is an oxygen atom, a sulfur atom or a group of the formula NR<sup>16</sup> and  
the residues R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup>  
are independently from each other a hydrogen atom, a alkyl, alkenyl, alkynyl  
heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl,  
heterocycloalkyl, aralkyl or a heteroaralkyl group, or two of the groups are  
together part of a cycloalkyl or heterocycloalkyl ring system,

V is a linker and W a polymer or a biomolecule.

2. Compounds according to claim 1, wherein the compound of the formula (I) is Tubulysin A.
3. Compounds according to the claims 1 or 2, wherein the polymer is a polyethylene glycol (PEG).
4. Compounds according to the claim 3, wherein the polyethylene glycol has a molecular weight of more than 30 kDa.
5. Compounds according to the claims 1 or 2, wherein the biomolecule is an antibody.

6. Use of a bioconjugate according to one of the claims 1 to 5 for the treatment of cancer.